ライフサイエンスコーパス: hypercholesterolemic

1 and PC diets were equally hyperlipidemic and hypercholesterolemic.

2 urveys, 60.7% to 64.3% of hypertensives were hypercholesterolemic.

3 vascular and platelet function in untreated hypercholesterolemics.

4 nted in hypertensive (215+/-44%; p=0.02) and hypercholesterolemic (172+/-71%; p=0.02) patients compar

5 n hypertensive (37+/-11%; p=0.01) but not in hypercholesterolemic (85+/-21%; p=0.78) patients compare

6 ega6/omega3 (0.08-0.21), hypocholesterolemic/hypercholesterolemic acid ratios (HH) (0.87-2.43), ather

7 ed system showed superior performance in all hypercholesterolemic adults (AUC=0.94-0.97) as well as i

8 Hypercholesterolemic adults (phase 1b) receiving low- to

9 Sixty-three mildly hypercholesterolemic adults who were preselected as poss

10 r, lowers cholesterol in healthy, moderately hypercholesterolemic adults.

11 e elevated in young, clinically asymptomatic hypercholesterolemic adults.

12 nstrated by a concise preparation of an anti-hypercholesterolemic agent.

13 ween relative weight and CVD risk factors in hypercholesterolemic and nonhypercholesterolemic childre

14 , it is clear that saturated fatty acids are hypercholesterolemic and that unsaturated fatty acids el

15 in/kexin type 9 (PCSK9) show promise as anti-hypercholesterolemic and, therefore, anti-atheroscleroti

16 me obese, hyperinsulinemic, hyperleptinemic, hypercholesterolemic, and hypertriglyceridemic.

17 w potential functional ingredients using the hypercholesterolemic animal model.

18 genesis and vascular leakage in diabetic and hypercholesterolemic animal models.

19 When fed a standard chow diet, these hypercholesterolemic animals developed significant ather

20 Tumors from hypercholesterolemic animals displayed significantly les

21 ts show that in vivo biopanning selection in hypercholesterolemic animals makes it possible to identi

22 ezetimibe disrupts the heterocomplex in only hypercholesterolemic animals.

23 induced atherosclerotic plaque formation in hypercholesterolemic ApoE mice by placing semiconstricti

24 ecretion.ApoA-V modulates atherosclerosis in hypercholesterolemic apoE null mice.

25 IDO deficiency in hypercholesterolemic ApoE(-/-) mice caused a significant

26 amplifies and accelerates atherosclerosis in hypercholesterolemic ApoE(-/-) or Ldlr(-/-) mice.

27 rophage ACAT1 accelerates atherosclerosis in hypercholesterolemic apoE-/- mice but has no effect when

28 d rHDL, infusion of PEG-rHDL (40 mg/kg) into hypercholesterolemic Apoe-/- mice led to more pronounced

29 PEG-rHDL was estimated after injection into hypercholesterolemic Apoe-/- mice; the half-life of pegy

30 i) monocyte subset increased dramatically in hypercholesterolemic apoE-deficient mice consuming a hig

31 C57Bl/6 wild-type and hypercholesterolemic apoE-deficient mice underwent trans

32 In hypercholesterolemic apoE-deficient mice, treatment with

33 ApoE(-/-), and ApoE(-/-)Glut1(+/-) mice into hypercholesterolemic ApoE-deficient mice, we found that

34 could restore normal endothelial function in hypercholesterolemic apolipoprotein (apo) E-null mice.

35 -poor lesions in the flow cessation model in hypercholesterolemic apolipoprotein E knockout (ApoE KO)

36 ces a significant reduction of restenosis in hypercholesterolemic apolipoprotein E knockout mice subj

37 be possible to interfere with restenosis in hypercholesterolemic apolipoprotein E knockout mice.

38 olysis, and osteogenesis in aortic valves of hypercholesterolemic apolipoprotein E-deficient mice (30

39 In hypercholesterolemic apolipoprotein E-deficient mice, ex

40 embrane injection into neointimal lesions of hypercholesterolemic apolipoprotein E-deficient mice.

41 senescence and atherosclerosis in aortas of hypercholesterolemic apolipoprotein E-deficient mice.

42 g and established atherosclerotic lesions in hypercholesterolemic apolipoprotein E-null mice.

43 y, we performed a series of assessments with hypercholesterolemic (apolipoprotein E-null [ApoE(-/-)])

44 , plasminogen-deficient mice were crossed to hypercholesterolemic, apolipoprotein E-deficient mice pr

45 These increases were ablated in hypercholesterolemic AT1A receptor-deficient mice.

46 e, type 2 diabetes, fatty liver disease, and hypercholesterolemic atherosclerosis.

47 cular disease risk in humans and develops in hypercholesterolemic atherosclerotic animal models.

48 Hypercholesterolemic AV calcification is attenuated by a

49 ly oxidized LDL subfraction present in human hypercholesterolemic but not normolipidemic plasma can i

50 After a 4-wk run-in period, 240 hypercholesterolemic but otherwise healthy men and women

51 In mildly hypercholesterolemic C57Bl/6 mice, presence of IA(b) and

52 creasing age and, in some cases, stronger in hypercholesterolemic children and girls.

53 Hypercholesterolemic children are increasingly being tre

54 n carbohydrate intake and HDL cholesterol in hypercholesterolemic children consuming fat-restricted d

55 with lower HDL-cholesterol concentrations in hypercholesterolemic children consuming reduced-fat diet

56 n blood lipids and other CVD risk factors in hypercholesterolemic children, although the strength of

57 wer affinity than LDLR and saturates only at hypercholesterolemic concentrations.

58 adaptive immune response prevails under the hypercholesterolemic conditions present in atheroscleros

59 efficacy in effector T-cell generation under hypercholesterolemic conditions.

60 and lipid accumulation in macrophages under hypercholesterolemic conditions.

61 h macrophages and is further activated under hypercholesterolemic conditions.

62 greater T cell responses than did APCs from hypercholesterolemic controls.

63 ation of vasa vasorum occurs in experimental hypercholesterolemic coronary arteries and may be a part

64 Compared with controls in hypercholesterolemic coronary arteries, there was a sign

65 Both protein-restricted and hypercholesterolemic dams exhibited significantly decrea

66 CFSE dilution analyses revealed that hypercholesterolemic DCs were equipotent in naive CD4(+)

67 e fed either a normal diet (control, n=7), a hypercholesterolemic diet (HCC, n=7), or a hypercholeste

68 iniswine were fed either a regular (N=13) or hypercholesterolemic diet (N=13) for 20 weeks.

69 8.5 to 16.0] for wild-type mice on chow and hypercholesterolemic diet and for apolipoprotein E-defic

70 ring of all groups (n=136) were fed a mildly hypercholesterolemic diet for up to a year and had simil

71 of TGF-beta signaling in Apoe(-/-) mice on a hypercholesterolemic diet led to development of aortic a

72 Rabbits fed on a hypercholesterolemic diet underwent bilateral iliac arte

73 a hypercholesterolemic diet (HCC, n=7), or a hypercholesterolemic diet with supplemental resveratrol

74 ere placed on a normal chow diet (N) or on a hypercholesterolemic diet without (HC) or with vitamin C

75 e placed on a normal diet (N; n = 7) or on a hypercholesterolemic diet without (HC; n = 6) or with ET

76 apolipoprotein E-deficient mice on chow and hypercholesterolemic diet, respectively; P<0.001).

77 poprotein E-deficient mice on either chow or hypercholesterolemic diet.

78 id and one femoral artery and ingestion of a hypercholesterolemic diet.

79 s was fed control chow and 8 groups were fed hypercholesterolemic diets Chol 1 (yielding plasma chole

80 (+)) mice or apolipoprotein (apo)E-deficient hypercholesterolemic (E(-)) mice.

81 ike 1 transporter with ezetimibe reduced the hypercholesterolemic effect of [Thr28, Nle31]-CCK in LDL

82 ld inform therapeutic approaches against its hypercholesterolemic effects.

83 are dysfunctional in a hyperglycemic and/or hypercholesterolemic environment.

84 Seventy-three hypercholesterolemic, free-living, postmenopausal women

85 Sixty-six hypercholesterolemic, free-living, postmenopausal women

86 embrane and improvement in relaxation in the hypercholesterolemic group given fish oils was seen (r=.

87 high-performance liquid chromatography in 49 hypercholesterolemic (HC) and 31 normocholesterolemic (N

88 to vasoactive drugs in normal (control) and hypercholesterolemic (HC) pigs.

89 d tomography after a 12-week normal (n=7) or hypercholesterolemic (HC, n=7) diet, RAS (n=6), or concu

90 DS AND In normocholesterolemic (NC, n=7) and hypercholesterolemic (HC, n=7) Yucatan male pigs, the le

91 s elevated (P<0.0005) in homozygous familial hypercholesterolemic (HFH) patients (85+/-5.5; n=38) com

92 Pigs were fed a normocholesterolemic (NC) or hypercholesterolemic (HL) diet for 10 days, reaching non

93 lectronegative LDL subfraction isolated from hypercholesterolemic human plasma with a recombinant pla

94 lation are associated with HSPC expansion in hypercholesterolemic human subjects.

95 t diet, male apoB/BATless mice became obese, hypercholesterolemic, hypertriglyceridemic, and hyperins

96 human volunteers and in homozygous familial hypercholesterolemic individuals.

97 lesterol concentrations in older middle-aged hypercholesterolemic individuals.

98 We show here, however, that hypercholesterolemic LDL receptor-deficient (LDLR(-/-))

99 in 2 dissimilar models of vascular disease: hypercholesterolemic LDL receptor-null (Ldlr(-/-)) mice

100 Forty-two hypercholesterolemic (LDL cholesterol > 3.36 mmol/L) sub

101 Study for nonobese 5-6-y-old black and white hypercholesterolemic (LDL cholesterol > 75th percentile;

102 total resistance to atherogenesis, even on a hypercholesterolemic (LDL receptor-null) background.

103 Hypercholesterolemic (LDL-cholesterol, >160 mg/dL) human

104 In hypercholesterolemic LDLR deficient mice (Ldlr(-/-)), BB

105 vasodilation and arterial wall thickness in hypercholesterolemic Ldlr(-/-) mice and Ldlr(-/-)/apoA-I

106 ctor 2 (KLF2) accelerates atherosclerosis in hypercholesterolemic Ldlr(-/-) mice due to the enhanced

107 , whereas the disrupted liver homeostasis in hypercholesterolemic Ldlr(-/-) mice led to intrahepatic

108 Compared to hypercholesterolemic Ldlr(-/-) mice treated with vehicle

109 Hypercholesterolemic LDLr(-/-)ApoB(100/100) mice are pro

110 Arterioles were isolated from hypercholesterolemic Ldlr-/- mice and from SCD mice that

111 t endothelial Kir channels are suppressed by hypercholesterolemic levels of lipoproteins in vitro and

112 ress and high atherosclerosis-prone areas of hypercholesterolemic low-density lipoprotein receptor kn

113 ogenesis, we investigated arterial growth in hypercholesterolemic low-density lipoprotein receptor(-/

114 In contrast, hypercholesterolemic low-density lipoprotein receptor/ap

115 Step I diet, 13 normocholesterolemic and 13 hypercholesterolemic men aged 20-50 y were enrolled in a

116 ), a measure of oxidative stress, in healthy hypercholesterolemic men and women.

117 ed FMD or other vascular function markers in hypercholesterolemic men and women.

118 Hypercholesterolemic men had age-adjusted absolute risk

119 d, crossover, metabolic-ward study, 7 mildly hypercholesterolemic men were fed 3 natural-food diets s

120 vention Study, a primary prevention trial in hypercholesterolemic men) exhibited a similar, although

121 ependent predictor of cardiovascular risk in hypercholesterolemic men.

122 needed to reduce blood lipids in moderately hypercholesterolemic men.

123 beta-glucan fiber in 15 free-living, obese, hypercholesterolemic men.

124 Step I diet in both normocholesterolemic and hypercholesterolemic men.

125 IGFBPs was replicated in wild-type SMCs from hypercholesterolemic mice and confirmed by silencing apo

126 xamined CD11c on blood leukocytes in apoE-/- hypercholesterolemic mice and found that compared with w

127 Similar metabolic adaptions occur in vivo in hypercholesterolemic mice and human subjects.

128 Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, mon

129 e that is assumed by the microvasculature of hypercholesterolemic mice and suggest that T lymphocytes

130 nt autoimmunity and suppress inflammation in hypercholesterolemic mice by attenuating lymphocyte chol

131 n or collapse of adventitial vasa vasorum in hypercholesterolemic mice by stimulating an increase in

132 Hypercholesterolemic mice deficient in Fn-EDA exhibit re

133 eractions and ameliorates ischemic injury in hypercholesterolemic mice independently of lipid-lowerin

134 Recent studies in hypercholesterolemic mice lacking apo E or the low-densi

135 Hypercholesterolemic mice lacking factors required for a

136 In published studies, hypercholesterolemic mice lacking HDL apoA-I or LDLr(-/-

137 ormal erythrocyte morphology was observed in hypercholesterolemic mice lacking the high-density lipop

138 The total serum from hypercholesterolemic mice leads to a small but significa

139 iae infection accelerates atherosclerosis in hypercholesterolemic mice predominantly through a TLR/My

140 One-day-old female hypercholesterolemic mice were administered a single dos

141 sin S inhibition attenuates atherogenesis in hypercholesterolemic mice with CRD.

142 l hypertrophy, inflammation, and fibrosis in hypercholesterolemic mice with diabetes, suggesting that

143 by genetic inactivation of the mttp gene in hypercholesterolemic mice with early aortic valve diseas

144 Finally, treatment of hypercholesterolemic mice with miR-33 inhibitors for 8 w

145 poprotein (oxLDL) and active immunization of hypercholesterolemic mice with oxLDL ameliorates atherog

146 in bone marrow cells reduced coagulation in hypercholesterolemic mice, consistent with a major role

147 In hypercholesterolemic mice, deficiency in endothelial aut

148 We now report that in hypercholesterolemic mice, deletion of syndecan 4 (S4(-/

149 macrophages and suppress atherosclerosis in hypercholesterolemic mice, displayed leukocytosis, a tra

150 progenitors in the bone marrow and spleen of hypercholesterolemic mice, effects that were partially r

151 O in macrophages promotes atherosclerosis in hypercholesterolemic mice, raising the possibility that

152 trated effective priming of naive T cells in hypercholesterolemic mice.

153 , deletion of LRP increases atherogenesis in hypercholesterolemic mice.

154 serum cholesterol levels in either normal or hypercholesterolemic mice.

155 ment of experimental AAAs in both normal and hypercholesterolemic mice.

156 on and early phases of atheroma formation in hypercholesterolemic mice.

157 l area observed in arteries allografted into hypercholesterolemic mice.

158 te the effect of NAMPT on atherosclerosis in hypercholesterolemic mice.

159 ed LDL contributions to the m-RCT pathway in hypercholesterolemic mice.

160 s to diabetic renal injury in hyperglycemic, hypercholesterolemic mice.

161 of a single dose of lipopolysaccharide into hypercholesterolemic mice.

162 imilar in the rPAI-1(23)- and saline-treated hypercholesterolemic mice.

163 Collectively, we suggest that the hypercholesterolemic milieu in the ApoE(-/-) mice is a f

164 D374Y-PCSK9 hypercholesterolemic minipigs (n=5) were instrumented wi

165 n coronary restenosis, PTCA was performed in hypercholesterolemic minipigs whose left anterior descen

166 of CD36, a class B scavenger receptor, in a hypercholesterolemic model of CKD.

167 to 53%, compared with offspring of untreated hypercholesterolemic mothers (P<0.01), with the greatest

168 At each time point, offspring of hypercholesterolemic mothers had 1.5- to 3-fold larger l

169 e expression between offspring of normo- and hypercholesterolemic mothers persist long after birth, s

170 Lesion progression in offspring of hypercholesterolemic mothers was greater than in all oth

171 ed increased protein content in offspring of hypercholesterolemic mothers.

172 were significantly regulated in offspring of hypercholesterolemic mothers.

173 and MyD88 signaling in atherosclerosis in a hypercholesterolemic mouse model, providing a pathophysi

174 ested in the angiotensin II (Ang II)-induced hypercholesterolemic mouse model.

175 but was not significantly different between hypercholesterolemic (n = 27) and nonhypercholesterolemi

176 BMI increased more in the hypercholesterolemic (n = 31) than in the nonhypercholes

177 n developing lesions of atherosclerosis from hypercholesterolemic nonhuman primates.

178 e intake of animal based protein (casein), a hypercholesterolemic nutrient.

179 valve stenosis would develop in genetically hypercholesterolemic old mice.

180 ession was increased in aortae obtained from hypercholesterolemic, oophorectomized animals supplement

181 ss of whether they were primed in vivo under hypercholesterolemic or control conditions, demonstratin

182 apoptosis and L4 had a mild effect, whereas hypercholesterolemic or normolipidemic L1-L3 had negligi

183 7% of cyclosporine-treated patients remained hypercholesterolemic (P < 0.05).

184 Whereas hypercholesterolemic p47(phox)+/- and WT mice exhibited

185 Thirty-six hypercholesterolemic participants (with LDL-cholesterol

186 (NC), 11 hypertensive patients (HT), and 12 hypercholesterolemic patients (HChol), arteries (interna

187 Untreated hypercholesterolemic patients (low-density lipoprotein c

188 Using a double-blind design, newly diagnosed hypercholesterolemic patients (n = 51) with asymptomatic

189 in healthy subjects (p=0.004 vs. saline) and hypercholesterolemic patients (p=0.03 vs. saline), but n

190 eous gluteal fat biopsies were taken from 16 hypercholesterolemic patients (serum total cholesterol,

191 When JTT-705 at 600 mg/day was given to hypercholesterolemic patients already on pravastatin 40

192 parate occasion, to ET-1 were measured in 12 hypercholesterolemic patients and 12 normal control subj

193 ery plaques were detected in 21 asymptomatic hypercholesterolemic patients at baseline.

194 broader lipid-altering effects when treating hypercholesterolemic patients at high risk for atheroscl

195 al subjects, 12 hypertensive patients and 10 hypercholesterolemic patients before and during NO synth

196 n-delivered nutrition intervention trial for hypercholesterolemic patients conducted in Worcester, Ma

197 apparently healthy individuals and genotyped hypercholesterolemic patients from clinical trial cohort

198 ous studies have shown that hypertensive and hypercholesterolemic patients have impaired endothelium-

199 Hypertensive but not hypercholesterolemic patients have impaired NO-dependent

200 Endothelial dysfunction in hypercholesterolemic patients may contribute to their ri

201 to examine the effects of fish oils given to hypercholesterolemic patients on small artery function i

202 inuing arginine treatment), the platelets of hypercholesterolemic patients once again became hyperagg

203 In addition, on a different day, six hypercholesterolemic patients received co-infusion of BQ

204 d longest evaluation of a PCSK9 inhibitor in hypercholesterolemic patients to date.

205 In hypercholesterolemic patients treated with losmapimod, r

206 and cytokine levels were compared between 11 hypercholesterolemic patients treated with simvastatin a

207 ctivity of endogenous endothelin-1 (ET-1) in hypercholesterolemic patients using antagonists of ET-1

208 gen showed increased aggregability (68.6% in hypercholesterolemic patients vs. 54.5% in normocholeste

209 ow-density lipoprotein apheresis in severely hypercholesterolemic patients who are refractory to lipi

210 s evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate

211 Eighteen asymptomatic hypercholesterolemic patients with documented aortic and

212 tography of LDL samples from 7 asymptomatic, hypercholesterolemic patients yielded subfractions L1-L5

213 a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously s

214 fy FBF from baseline (p = 0.78); however, in hypercholesterolemic patients, BQ-123 administration res

215 In hypercholesterolemic patients, the vasodilator response

216 isoprostanes was significantly increased in hypercholesterolemic patients, whereas substrate AA in u

217 r activity of endogenous ET-1 is enhanced in hypercholesterolemic patients, whereas their sensitivity

218 oves nitric oxide-mediated vasodilatation in hypercholesterolemic patients, which is consistent with

219 te the increased platelet reactivity seen in hypercholesterolemic patients.

220 rate ingestion improves vascular function in hypercholesterolemic patients.

221 These results suggest novel ways to manage hypercholesterolemic patients.

222 At diet completion, hypercholesterolemic PCSK9-HFD had significantly (P<0.05

223 herosclerotic lesion burden and phenotype in hypercholesterolemic PD-L1/2(-/-)LDLR(-/-) mice and LDLR

224 Freshly isolated APCs from hypercholesterolemic PD-L1/2(-/-)LDLR(-/-) mice stimulat

225 We conclude that hypercholesterolemic people should keep their consumptio

226 American diet on blood lipids in moderately hypercholesterolemic persons.

227 Hypercholesterolemic pigs underwent MI induction (90 min

228 Nineteen hypercholesterolemic pigs with preexisting coronary arte

229 elial cells freshly isolated from healthy or hypercholesterolemic pigs.

230 immunoreactivity in the coronary arteries of hypercholesterolemic pigs.

231 and inflammation prospectively dampen HRV in hypercholesterolemic pigs.

232 n of vasa vasorum in normal and experimental hypercholesterolemic porcine coronary arteries, using a

233 Hypercholesterolemic postmenopausal women (n = 20, mean

234 operties that may benefit the vasculature of hypercholesterolemic postmenopausal women, even if they

235 diameter in normocholesterolemic and mildly hypercholesterolemic postmenopausal women.

236 d profile in normocholesterolemic and mildly hypercholesterolemic postmenopausal women.

237 the vascular responses to these therapies in hypercholesterolemic postmenopausal women.

238 content were investigated in 66 free-living, hypercholesterolemic, postmenopausal women during a 6-mo

239 We used a hypercholesterolemic rabbit model of atherosclerosis to

240 restenosis in atherosclerotic arteries in a hypercholesterolemic rabbit model.

241 his hypothesis, we developed an experimental hypercholesterolemic rabbit model.

242 labeled with (64)Cu for noninvasive PET in a hypercholesterolemic rabbit with atherosclerotic-like le

243 In the hypercholesterolemic rabbit, HDL levels can be increased

244 s vasodilatory responses to acetylcholine in hypercholesterolemic rabbits and atherosclerotic humans.

245 yte adhesion and subendothelial migration in hypercholesterolemic rabbits and whether any gender diff

246 y found that administration of L-arginine to hypercholesterolemic rabbits induces regression of preex

247 Atherosclerotic aortas from hypercholesterolemic rabbits produced high levels of rea

248 shown that gene therapy with NO synthase in hypercholesterolemic rabbits substantially reverses the

249 The thoracic aorta of hypercholesterolemic rabbits underwent mechanical remova

250 In hypercholesterolemic rabbits, however, ischemic PC faile

251 a significant vascular protective effect in hypercholesterolemic rabbits, most likely by attenuation

252 C in normocholesterolemic rabbits but not in hypercholesterolemic rabbits.

253 ts compared with control stents implanted in hypercholesterolemic rabbits.

254 c arteries of 40 normocholesterolemic and 16 hypercholesterolemic rabbits.

255 eointimal formation and arterial stenosis in hypercholesterolemic rabbits.

256 s in balloon-injured iliofemoral arteries of hypercholesterolemic rabbits.

257 In the aorta of hypercholesterolemic rats, lipid deposits were distribut

258 th muscle cells was significantly greater in hypercholesterolemic recipients than in normocholesterol

259 ndices (higher atherogenic, thrombogenic and hypercholesterolemic saturated fatty acids and lower des

260 ificantly reduced serum LDL-C in healthy and hypercholesterolemic statin-treated subjects, including

261 Twenty-eight hypercholesterolemic subjects (LDL cholesterol >/=3.36 m

262 was performed and included fifty moderately hypercholesterolemic subjects (mean LDL cholesterol = 16

263 Hypercholesterolemic subjects (n = 120, ages 21 to 80 ye

264 Hypercholesterolemic subjects (n = 23) were assigned to

265 20; P<0.05) was also increased in moderately hypercholesterolemic subjects (n=24) compared with their

266 dykinin-mediated vasodilation in healthy and hypercholesterolemic subjects (P<0.001).

267 f effects in normocholesterolemic and mildly hypercholesterolemic subjects are unclear.

268 Twenty-one mildly hypercholesterolemic subjects completed a randomized, do

269 mg) to a placebo administered once daily to hypercholesterolemic subjects greater than 18 years of a

270 ease (CAD) progression and cardiac events in hypercholesterolemic subjects is now widely accepted.

271 poprotein cholesterol (LDL-C) in healthy and hypercholesterolemic subjects on statin therapy.

272 esterolemic control subjects, platelets from hypercholesterolemic subjects stimulated with 5 microgra

273 Mildly hypercholesterolemic subjects were randomized to backgro

274 dose pravastatin (80 mg/day) administered to hypercholesterolemic subjects with chronic liver disease

275 As an extension of our prior study, hypercholesterolemic subjects with no known coronary art

276 Hypercholesterolemic subjects with no other known cause

277 sma total cholesterol and LDL cholesterol in hypercholesterolemic subjects, but the responsible soy c

278 iable effects on oxidative stress markers in hypercholesterolemic subjects.

279 atory cardiovascular disease risk factors in hypercholesterolemic subjects.

280 n to be hypocholesterolemic, particularly in hypercholesterolemic subjects.

281 e-living normocholesterolemic and moderately hypercholesterolemic subjects.

282 We used a hypercholesterolemic swine model of chronic ischemia to

283 In the familial hypercholesterolemic swine model of femoral restenosis,

284 eration and healing response in the familial hypercholesterolemic swine model of femoral restenosis.

285 Hypercholesterolemic swine showed coronary endothelial d

286 Hypercholesterolemic swine showed no net increase in per

287 applicable methods was markedly inhibited in hypercholesterolemic swine with coronary endothelial dys

288 ced coronary atherosclerosis in diabetic and hypercholesterolemic swine.

289 c response to chronic myocardial ischemia in hypercholesterolemic swine.

290 ation in the femoral arteries of 18 familial hypercholesterolemic swine.

291 cardial perfusion was significantly lower in hypercholesterolemic than in normocholesterolemic swine,

292 nificantly lower in the lateral territory of hypercholesterolemic versus normocholesterolemic animals

293 Healthy mildly hypercholesterolemic volunteers (23 women, 17 men), with

294 concentrations in postmenopausal, moderately hypercholesterolemic women.

295 mia but not in normocholesterolemic or midly hypercholesterolemic women.

296 and LDL-cholesterol concentrations in mildly hypercholesterolemic young men.

297 apeutic effects on vascular fatty lesions of hypercholesterolemic zebrafish by atorvastatin is notabl

298 henotypes are present in large quantities in hypercholesterolemic zebrafish larvae and support the us

299 A novel hypercholesterolemic zebrafish model has been developed

300 Using hypercholesterolemic zebrafish, we present an orchestrat